

## Retraction of Statement

**Neurotech International Limited (ASX: NTI)** ('Neurotech', 'NTI' or 'the Company'), refers to its announcement on 20 March 2025 titled "Neurotech Presentation at NWR Virtual Healthcare Conference" and the presentation slides annexed to that announcement ('Presentation').

Following recent discussions with the ASX, the Company wishes to retract the statement regarding 'Market Opportunity' in the 'NTI164 Commercial Opportunity' diagram included on slide 10 of the Presentation.

The Company advises that it does not have a reasonable basis for making the statement regarding 'Market Opportunity' and investors should not rely on the retracted information as a basis for an investment decision.

### Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via [info@neurotechinternational.com](mailto:info@neurotechinternational.com)

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.